Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19079070 | FORMULATIONS OF VIMSELTINIB | March 2025 | May 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19061509 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | February 2025 | May 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19061577 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | February 2025 | May 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19046435 | COMPOSITIONS AND METHODS FOR MINIMUM RISK PEST CONTROL | February 2025 | April 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19031698 | NICOTINAMIDE RIBOSIDE HYDROGEN MALATE CRYSTAL, AND ITS PREPARATION METHOD AND APPLICATION | January 2025 | April 2025 | Allow | 3 | 0 | 0 | No | No |
| 19028631 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | January 2025 | May 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 19025101 | CRYSTAL FORMS OF BETA-NICOTINAMIDE MONONUCLEOTIDE | January 2025 | June 2025 | Allow | 5 | 1 | 0 | No | No |
| 19023407 | ANTHRACENE-BASED COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF AS SOLAR THERMAL FUEL | January 2025 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18995514 | Process For the Production of Methanol and Hydrogen from Methane Using a Solid Metal Hydroxide Reagent | January 2025 | June 2025 | Allow | 5 | 0 | 0 | No | No |
| 19018702 | ILOPROST COMPOSITIONS AND FORMULATIONS THEREOF | January 2025 | July 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19017364 | ANTI-MICROBIAL TREATMENT FOR SEEDS AND CROPS | January 2025 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19002520 | COMPOUNDS FOR ACTIVATING A SEROTONIN RECEPTOR | December 2024 | May 2025 | Allow | 5 | 1 | 0 | No | No |
| 19002103 | POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | December 2024 | June 2025 | Allow | 6 | 1 | 0 | No | No |
| 18990585 | USE OF MARIBAVIR IN TREATMENT REGIMENS | December 2024 | May 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18987521 | PROCESS FOR PREPARING 7-CHLORO-6-FLUORO-1-(2-ISOPROPYL-4-METHYLPYRIDIN-3-YL)PYRIDO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE | December 2024 | June 2025 | Allow | 6 | 1 | 0 | No | No |
| 18968658 | PROCESS FOR REDUCING BY-PRODUCTS IN BISPHENOL A REACTION SYSTEM | December 2024 | May 2025 | Allow | 6 | 0 | 0 | No | No |
| 18870764 | COSMETIC COMPOSITION | December 2024 | April 2025 | Allow | 4 | 0 | 0 | No | No |
| 18964637 | GLYCOSYLATION METHOD INVOLVING TRIVALENT IODINE REAGENT | December 2024 | February 2025 | Allow | 2 | 0 | 0 | No | No |
| 18963493 | DEVICE AND METHOD FOR REFINING ETHANOL | November 2024 | January 2025 | Allow | 2 | 0 | 0 | No | No |
| 18963281 | METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS, NICOTINAMIDE RIBOFURANOSIDE SALTS AS SUCH, AND USES THEREOF | November 2024 | April 2025 | Allow | 5 | 1 | 0 | No | No |
| 18959040 | NOVEL PHENYLPYRAZOLE INSECTICIDE COMPOUNDS AND COMPOSITIONS | November 2024 | May 2025 | Allow | 6 | 1 | 0 | No | No |
| 18951543 | PLEUROMUTILIN DERIVATIVE CONTAINING A THIAZOLO[5,4-C]PYRIDINE SIDE CHAIN, AND A PREPARATION METHOD AND APPLICATION THEREOF | November 2024 | March 2025 | Allow | 4 | 0 | 1 | No | No |
| 18935099 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | November 2024 | January 2025 | Allow | 2 | 0 | 0 | No | No |
| 18935253 | MODULATORS OF DCN-1 AND METHODS OF USE THEREOF | November 2024 | January 2025 | Allow | 2 | 0 | 0 | No | No |
| 18932667 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAME | October 2024 | April 2025 | Allow | 5 | 1 | 0 | No | No |
| 18929263 | SELECTIVE LIGANDS FOR TAU AGGREGATES | October 2024 | January 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 18860494 | PROCESS FOR THE PREPARATION OF 2,4,6-TRIIODOPHENOL DERIVATIVES | October 2024 | February 2025 | Allow | 4 | 0 | 0 | No | No |
| 18924252 | Oral (17-�)-3-Oxoandrost-4-EN-17-YL Tridecanoate Therapy | October 2024 | January 2025 | Allow | 3 | 1 | 0 | No | No |
| 18924505 | BISPHENOL A PREPARATION PROCESS AND DEVICE THEREOF | October 2024 | April 2025 | Allow | 5 | 0 | 0 | No | No |
| 18918161 | PTPN2/PTP1B Degrader and Therapeutic Method Thereof | October 2024 | December 2024 | Allow | 2 | 0 | 0 | No | No |
| 18856957 | SYNTHESIS AND PURIFICATION OF CBDA | October 2024 | February 2025 | Allow | 4 | 0 | 0 | No | No |
| 18914975 | AZAINDOLE ROCK INHIBITORS | October 2024 | January 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 18910861 | HYDROGEL NANOBEADS FOR ADSORPTION OF POLLUTANTS FROM WASTEWATER | October 2024 | March 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18910839 | HYDROGEL NANOBEADS FOR ADSORPTION OF POLLUTANTS FROM WASTEWATER | October 2024 | February 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18910667 | PROCESSES AND SYSTEMS FOR PRODUCTION OF SUSTAINABLE AVIATION FUEL FROM SYNGAS VIA MIXED ALCOHOLS | October 2024 | March 2025 | Allow | 6 | 1 | 0 | No | No |
| 18853657 | ACETYL SALICYLIC ACID COMPOSITION FOR INTRAVENOUS ADMINISTRATION, ITS STORAGE, PRODUCTION AND USE | October 2024 | June 2025 | Allow | 8 | 1 | 0 | No | No |
| 18898132 | GAMMA-HYDROXYBUTYRATE COMPOSITIONS HAVING IMPROVED PHARMACOKINETICS IN THE FED STATE | September 2024 | March 2025 | Allow | 5 | 1 | 0 | No | No |
| 18896739 | DEVICE AND PROCESS FOR PREPARING SEBACIC ACID THROUGH ELECTROMAGNETIC INDUCTION HEATING COUPLED WITH DRY CONSTANT-TEMPERATURE ALKALINE HYDROLYSIS | September 2024 | January 2025 | Allow | 4 | 1 | 0 | No | No |
| 18892950 | REDUCING THE RISK OF VIRAL INFECTION DUE TO VIRAL CONTAMINATED FEED | September 2024 | March 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18893901 | METHOD FOR PREPARING 1,3-PROPANEDIOL WITH HIGH SPACE-TIME YIELD AND HIGH CONCENTRATION | September 2024 | June 2025 | Allow | 9 | 2 | 0 | No | No |
| 18889398 | METHODS AND KITS USEFUL FOR DIAGNOSIS OF HUMAN PAPILLOMAVIRUS (HPV) | September 2024 | February 2025 | Allow | 4 | 2 | 0 | No | No |
| 18885065 | GLP-1R Agonist and Therapeutic Method Thereof | September 2024 | December 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18829583 | METHANOL PRODUCTION FROM METHANE UTILIZING A SUPPORTED CHROMIUM CATALYST | September 2024 | March 2025 | Allow | 6 | 1 | 0 | No | No |
| 18828652 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | September 2024 | April 2025 | Allow | 7 | 2 | 0 | No | No |
| 18814583 | LINEAR BORON-DIPYRROMETHENE ELECTRON DONOR HAVING 180� COORDINATION INCLUDED ANGLE AND SUPRAMOLECULAR METAL MACRO-RING, AND SYNTHESIS PROCESSES THEREFOR AND APPLICATIONS THEREOF | August 2024 | March 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18813024 | BETA-GLUCAN-RICH LENTINULA EDODES POLYSACCHARIDE AND PREPARATION METHOD THEREOF | August 2024 | November 2024 | Allow | 2 | 0 | 0 | No | No |
| 18812284 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | August 2024 | December 2024 | Allow | 4 | 1 | 0 | No | No |
| 18812980 | NO DONOR COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | August 2024 | January 2025 | Allow | 4 | 0 | 1 | Yes | No |
| 18808641 | COMPOUNDS FOR FGFR INHIBITION | August 2024 | February 2025 | Allow | 6 | 0 | 1 | No | No |
| 18808138 | Compositions and Methods for Treating Endocrine Diseases and Disorders | August 2024 | October 2024 | Allow | 2 | 0 | 0 | No | No |
| 18807247 | SYSTEM AND METHOD FOR TRIGLYCERIDE MANUFACTURE | August 2024 | June 2025 | Allow | 10 | 1 | 1 | Yes | No |
| 18806346 | SYSTEM FOR AND METHOD OF PRODUCING PURE STARCH SLURRY AND ALCOHOL BY USING A PROCESS COMBINING WET CORN MILLING AND A DRY CORN MILLING PROCESSES | August 2024 | March 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18794655 | PROCESS FOR DEBROMINATION OF NOVEL BROMINATED FLAME RETARDANTS USING Zn-BASED ADDITIVES | August 2024 | December 2024 | Allow | 4 | 0 | 0 | No | No |
| 18792393 | ARNATAR COMPOUNDS AND METHODS FOR ENHANCED CELLULAR UPTAKE | August 2024 | October 2024 | Allow | 3 | 0 | 0 | No | No |
| 18792077 | COLON-TARGETED ACTIVE AGENT DELIVERY CARRIER AND USES THEREOF | August 2024 | June 2025 | Allow | 10 | 3 | 0 | Yes | No |
| 18790828 | Dosage Regimen | July 2024 | April 2025 | Allow | 9 | 1 | 0 | No | No |
| 18790366 | CANNABIDIOLIC ACID COCRYSTALS | July 2024 | February 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18789494 | CHEMICAL COLLECTION AND PROCESSING VESSEL AND METHODS FOR FLUID TRANSFER AT SEA | July 2024 | April 2025 | Allow | 8 | 2 | 0 | No | No |
| 18785350 | PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | July 2024 | April 2025 | Allow | 9 | 2 | 0 | No | No |
| 18786055 | PHOTOCATALYTIC REDUCTION OF CARBON DIOXIDE USING Fe2TiO5 NANOSHEETS | July 2024 | December 2024 | Allow | 5 | 0 | 0 | No | No |
| 18783394 | KRAS G12C INHIBITORS | July 2024 | October 2024 | Allow | 2 | 0 | 0 | No | No |
| 18783039 | NANO PESTICIDAL FORMULATION AND PREPARATION METHOD THEREOF | July 2024 | March 2025 | Allow | 8 | 2 | 0 | No | No |
| 18832248 | GINGERENONE A PRODRUGS AS SENSOTHERAPEUTICS AND METHODS OF USE | July 2024 | April 2025 | Allow | 8 | 0 | 1 | Yes | No |
| 18777489 | VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | July 2024 | April 2025 | Allow | 8 | 2 | 0 | No | No |
| 18777473 | VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | July 2024 | January 2025 | Allow | 6 | 1 | 0 | No | No |
| 18777501 | VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | July 2024 | January 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18775678 | POLYSILANE METHACRYLIC COMPOUNDS AND METHODS OF MAKING THEM | July 2024 | September 2024 | Allow | 2 | 0 | 0 | No | No |
| 18775693 | POLYSILANE METHACRYLIC COMPOUNDS AND METHODS OF MAKING THEM | July 2024 | September 2024 | Allow | 2 | 0 | 0 | No | No |
| 18769736 | METHOD FOR OBTAINING SULFATED NANOPARTICLES OF CELLULOSE AND MANNAN FROM ENDOSPERMS | July 2024 | March 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 18763243 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | July 2024 | December 2024 | Allow | 5 | 1 | 0 | No | No |
| 18763277 | PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | July 2024 | September 2024 | Allow | 2 | 1 | 0 | No | No |
| 18763258 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | July 2024 | December 2024 | Allow | 5 | 1 | 0 | No | No |
| 18762939 | REGIMENS FOR TREATING HIV INFECTIONS AND AIDS | July 2024 | October 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18760458 | DUAL MODULATOR OF MGLUR5 AND 5-HT2A RECEPTOR, AND USE THEREOF | July 2024 | June 2025 | Allow | 11 | 1 | 0 | No | No |
| 18751014 | PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER | June 2024 | February 2025 | Allow | 8 | 1 | 0 | No | No |
| 18750829 | POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | June 2024 | May 2025 | Allow | 10 | 2 | 0 | Yes | No |
| 18743681 | Method Of Preparing A Hybrid Inorganic-Organic MOF Compound With High Photoluminescence (PL) Quantum Yields (PLQY) | June 2024 | January 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18740657 | PROCESS AND APPARATUS FOR THE PREPARATION OF ALKYLENE GLYCOL | June 2024 | January 2025 | Allow | 7 | 0 | 0 | No | No |
| 18736662 | ELECTRONICALLY STRONGLY COUPLED 1,4-DIVINYLPHENYLENEBRIDGED DIRUTHENIUM COMPLEX BEARING TWO Ru(CO)(2-MERCAPTOPYRIDINE)(PiPr3)2 MOIETIES AS AN INORGANIC CATALYST | June 2024 | May 2025 | Allow | 11 | 1 | 1 | No | No |
| 18716802 | LOW BIURET UREA PRODUCTION | June 2024 | February 2025 | Allow | 8 | 1 | 0 | No | No |
| 18732056 | FERROCENE-SUBSTITUTED ORGANOMETALLIC COMPLEXES | June 2024 | December 2024 | Allow | 6 | 0 | 1 | No | No |
| 18680287 | ESKETAMINE FOR THE TREATMENT OF DEPRESSION | May 2024 | March 2025 | Abandon | 9 | 1 | 0 | No | No |
| 18680557 | AEROSOL AND TOPICAL ADMINISTRATION OF A FORMULATION CONTAINING CYCLODEXTRIN, QUERCETIN AND ZINC, IN COMBINATION OR SEPARATELY, TO MITIGATE INFECTION BY ENVELOPED VIRUSES | May 2024 | June 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18714848 | A LIPID COMPOUND CONTAINING CARBAMATE BOND AND APPLICATIONS THEREOF | May 2024 | January 2025 | Allow | 7 | 1 | 0 | No | No |
| 18676985 | Method for Prolonging Half-life of Theanine In Vivo | May 2024 | September 2024 | Allow | 4 | 2 | 0 | No | No |
| 18672453 | TRANSITION METAL COMPLEX ASSISTED GREEN HYDROLYSIS FOR NANOCELLULOSE EXTRACTION | May 2024 | November 2024 | Allow | 6 | 1 | 0 | No | No |
| 18672651 | Modified Nucleoside Phosphoramidites | May 2024 | June 2025 | Allow | 13 | 1 | 0 | No | No |
| 18670619 | EFFECTIVE TREATMENT OF DEPRESSION IN PATIENTS HAVING IMPAIRED LEARNING AND/OR MEMORY OR CERTAIN EEG CHARACTERISTICS WITH A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT | May 2024 | April 2025 | Abandon | 11 | 2 | 0 | No | No |
| 18667200 | METHOD FOR PREPARING PINACOLONE | May 2024 | November 2024 | Allow | 6 | 1 | 0 | No | No |
| 18665923 | FUSED RING DERIVATIVE HAVING MGAT-2 INHIBITORY ACTIVITY | May 2024 | June 2025 | Allow | 13 | 1 | 1 | Yes | No |
| 18664971 | CD206 TARGETED DRUG DELIVERY VEHICLES CARRYING NOVEL BISPHOSPHONATE DRUG PAYLOADS VIA A DEGRADABLE LINKER | May 2024 | January 2025 | Allow | 8 | 1 | 0 | No | No |
| 18662947 | INHIBITORS OF BUNYAVIRIDAE AND USES THEREOF | May 2024 | March 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18662301 | Preparation method and application of water-soluble chlorhexidine hyaluronate antibacterial agents | May 2024 | December 2024 | Allow | 7 | 2 | 0 | Yes | No |
| 18660547 | PREPARATION METHOD FOR POLYSACCHARIDE SPHERICAL GEL RESIN | May 2024 | April 2025 | Allow | 11 | 2 | 0 | No | No |
| 18659052 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | May 2024 | June 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18657754 | PREPARATION SYSTEMS AND PREPARATION METHODS FOR HIGH-QUALITY XYLITOL CRYSTALS | May 2024 | September 2024 | Allow | 5 | 1 | 0 | No | No |
| 18656519 | TREATMENT OF ADENOVIRUS INFECTION OR DISEASE ASSOCIATED WITH ADENOVIRUS INFECTION | May 2024 | March 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18654660 | LIPID FORMULATIONS FOR GENE EDITING | May 2024 | January 2025 | Allow | 9 | 1 | 0 | No | No |
| 18653713 | PHARMACEUTICAL COMPOSITION | May 2024 | July 2025 | Allow | 14 | 3 | 1 | Yes | No |
| 18652647 | CHEMICAL COLLECTION AND PROCESSING VESSEL AND METHODS FOR FLUID TRANSFER AT SEA | May 2024 | January 2025 | Allow | 8 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for group 1690.
With a 39.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 34.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Group 1690 is part of Technology Center 1600. This group has examined 8,669 patent applications in our dataset, with an overall allowance rate of 82.8%. Applications typically reach final disposition in approximately 30 months.
Applications in Group 1690 receive an average of 1.68 office actions before reaching final disposition. The median prosecution time is 30 months.
This group-level data aggregates statistics across multiple art units. For more targeted prosecution strategies, review the individual art unit and examiner statistics within this group.
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.